As EGFR hyperactivity is considered critical in the initiation and progression of epithelial derived tumours, EGFR tyrosine kinase inhibitors have therapeutic potential as chemopreventative agents for gastrointestinal neoplasia [30]. Here, EGFR is linked to neoplasm.